Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01602952|
Recruitment Status : Completed
First Posted : May 21, 2012
Last Update Posted : August 29, 2018
A Phase I/II multicenter study of IY5511HCl in Philadelphia chromosome positive chronic myeloid leukemia patients without optimal response or tolerance to Bcr-Abl tyrosine kinase inhibitors (Imatinib and/ or Dasatinib, Nilotinib) In this study, The efficacy and safety of CML patients who are resistant or intolerable to imatinib in the Chronic and Accelerated phases.
1. To investigate the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicity (DLT) of oral Radotinib HCl bid (twice daily) in the Philadelphia chromosome-positive CML subjects who are resistant, suboptimal responsive, or intolerant to imatinib OR resistant or intolerant to at least one second-generation targeted anticancer agent while being resistant, suboptimal responsive, or intolerant to imatinib simultaneously.
- To investigate safety of oral Radotinib HCl in CML patients who are resistant or intolerable to imatinib in the chronic and accelerated phases.
- To evaluate hematologic and cytogenetic efficacy of oral Radotinib HCl in CML patients who are resistant or intolerable to imatinib in the chronic and accelerated phases.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Philadelphia Chromosome Hematologic Diseases||Drug: Radotinib||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||85 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Multicenter Study of IY5511HCl in Philadelphia Chromosome Positive Chronic Myeloid Leukemia Patients Without Optimal Response or Tolerance to Bcr-Abl Tyrosine Kinase Inhibitors (Imatinib and/ or Dasatinib, Nilotinib)|
|Study Start Date :||July 2008|
|Actual Primary Completion Date :||October 2012|
|Actual Study Completion Date :||July 13, 2018|
Phase 1 : 200mg/kg or 1200mg/m^2
Phase 2 : 400mg Bid
50mg, 100mg or 200mg Capsule BID
Other Name: IY5511HCl
- To investigate the Maximum Tolerated Dose(Phase 1) [ Time Frame: 12 month ]Radotinib will be given orally twice daily. Dose will be increased until it reaches MTD or the blood concentration of Radotinib stops rising
- Rate of Complete hematologic response(CHR)(Phase 2) [ Time Frame: 12 months ]Main parameters for response assessment in the chronic and accelerated phases include Major Hematologic Responses (MR; No Evidence of Leukemia or NEL + Complete Hematologic Response or CHR) lasting for 4 weeks and at least one major cytogenetic response (MCyR)
- To investigate the Dose Limiting Toxicity(Phase 1) [ Time Frame: 12 months ]The initial cohort will include 3 subjects who will receive 100mg Radotinib daily. If DLT is observed in one of the 3 subjects, the same dose will be given to 3 more subjects to evaluate safety.
- Rate of complete Cytogenetic Response(CCyR)(Phase 2) [ Time Frame: 12 months ]Cytogenetic response rate will be calculated as the percentage of Ph+ bone marrow metaphases as follows at least 20 bone marrow metaphases should be analyzed.
- Adverse events(Phase 1& Phase 2) [ Time Frame: 12 months ]All adverse events recorded during the study will be itemized and summarized. Severity, relation to the study medication, and seriousness will be summarized for each adverse event.
- Progression-free survival or PFS [ Time Frame: 12 months ]It is defined as the duration from the first day of administration to the earliest day of disease progression or death for certain causes. In subjects who have shown response, disease progression is defined as loss of MCyR.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01602952
|Mumbai, Maharashtra, India, 741-234|
|Mumbai, Mazagaon, India, 512-364|
|Korea, Republic of|
|Daegu, Buk-gu, Korea, Republic of, 511-230|
|Jeonju, Deokjin-gu, Korea, Republic of, 212-789|
|Ulsan, Dong-gu, Korea, Republic of, 411-978|
|Anyang-si, Dongan-gu, Korea, Republic of, 751-231|
|Hwasun, Hwasun-eup, Korea, Republic of, 322-511|
|Seoul, Jongro-ku, Korea, Republic of, 231-855|
|Busan, Seo-gu, Korea, Republic of, 400-321|
|Seoul St. Mary's hospital|
|Seoul, Seocho-gu, Korea, Republic of|
|Suwon, Yeongtong-gu, Korea, Republic of, 781-512|
|Bangkok, Phyathai, Thailand, 215-714|
|Study Director:||IL-yang Pharm||IL-YANG Pharmaceutical.Co.,Ltd.|